High Doses Of Immunoglobulin May Help Combat COVID-19 Vaccin
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
It has been found that vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare side effect of adenoviral vector vaccines against Covid-19. Scientists have demonstrated a new lifesaving treatment for people suffering from vaccine-related blood clots. They are recommending two treatments, a combination of anti-clotting drugs with high doses of intravenous immunoglobulin, to combat vaccine-induced immune thrombotic thrombocytopenia (VITT).

The treatment's effectiveness was described in a report describing three Canadian patients who received the AstraZeneca vaccine, and who subsequently developed VITT. Two suffered clotting in their legs and the third had clots blocking arteries and veins inside their brain. While the study patients were older, many VITT cases have affected younger people.

The lab's scientists devised an effective VITT test and treatment by building on their previous investigations of heparin-induced thrombocytopaenia (HIT). While the two conditions are similar, using a standard HIT antibody test to detect VITT can yield false-negative results. This led the scientists to modify the HIT test to detect VITT-specific antibodies that are found, albeit rarely, in patients who had a COVID-19 vaccine.

Subsequent lab tests on patient blood samples showed how high doses of immunoglobulin coupled with blood-thinner medications shut down platelet activation and stopped clot formation. The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of Covid-19 vaccine-induced immune thrombotic thrombocytopenia (VITT), conclude researchers.

Dr. T●●●●z H●●●●●●i and 3 others like this2 shares